Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 1038

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 3
Chunk 1038
---
,605

    $
    1.33
  
    A
    consultant
     
    April
    17, 2024
     
    Granted
     
    Non-qualified
    Stock Option; Common Stock

    67,500

    $
    1.33

The
above issuances/sales were made pursuant to an exemption from registration as set forth in Section 4(a)(2) of the Securities Act and/or
Rule 506 of Regulation D promulgated under the Securities Act.

82

Purchases
of Equity Securities by the Issuer and Affiliated Purchasers

None. 

Transfer
Agent

The
Company’s transfer agent is Equiniti Trust Company. The transfer agent’s address is 1110 Centre Pointe Curve, Suite 101,
Mendota Heights, Minnesota 55120, and its telephone number is (800) 401-1957.

ITEM
6. [RESERVED]

ITEM
7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Special
Note Regarding Forward-Looking Statements

All
statements other than statements of historical fact included in this Annual Report on Form 10-K, including, without limitation, statements
under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s
financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements.
When used in this Annual Report on Form 10-K, words such as “anticipate,” “believe,” “estimate,”
“expect,” “intend” and similar expressions, as they relate to us or the Company’s management, identify
forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and
information currently available to, the Company’s management. Actual results could differ materially from those contemplated by
the forward-looking statements as a result of certain factors detailed in our filings with the SEC.

The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial
statements and the notes thereto contained elsewhere in this Annual Report on Form 10-K. Certain information contained in the discussion
and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Unless the context otherwise requires,
“JNS,” “we,” “us,” “our,” or the “Company” refers to Jupiter Neurosciences,
Inc.

Business